Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock, down previously from $13.00.
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024